Galectin-3: A Cardiomyocyte Antiapoptotic Mediator at 24-Hour Post Myocardial Infarction
- PMID: 32246616
- DOI: 10.33594/000000220
Galectin-3: A Cardiomyocyte Antiapoptotic Mediator at 24-Hour Post Myocardial Infarction
Abstract
Background/aims: Galectin 3 (GAL-3) is a beta galactoside binding lectin that has different roles in normal and pathophysiological conditions. GAL-3 has been associated with heart failure and was linked to increased risk of death in a number of studies. GAL-3 was found to be up regulated in animal models of heart failure as well as myocardial infarction (MI). The objective of his study is to test if high GAL-3 after myocardial infarction has a protective role on the heart through its anti-apoptotic and anti-necrotic functions.
Methods: Male C57B6/J mice and GAL-3 knockout (KO) mice were used for permanent ligation of the left anterior descending artery of the heart to create infarction in the anterior myocardium. Heart and plasma samples were collected 24 hours after the induction of MI and were used for immunohistochemistry, Tunnel procedure, electron microscopy and enzyme linked immunosorbent assay (ELISA).
Results: Our results show that the significant increase in GAL-3 levels in the left ventricle at 24-hour following MI is associated with significant lower levels of pro-apoptotic proteins; cytochrome c, Bax, annexin V, cleaved caspase-3 and a higher levels of anti-apoptotic protein Bcl2 in GAL-3 wild MI group than GAL-3 KO group. We also have identified the anti-apoptotic activity of GAL-3 is mediated through a significant increase in Akt-1, NF kappa-B and beta- catenin proteins. In addition, we have identified the antiapoptotic activity is mediated through a significant lower levels of cathepsin-D protein.
Conclusion: We conclude that the increased levels of GAL-3 at 24-hour following MI regulate antiapoptotic mechanisms in the myocardium that will shape the future course of the disease. We also identified that the anti-apoptotic mechanisms are likely mediated through interaction of GAL-3 with Akt-1, NF kappa-B, beta- catenin and cathepsin D proteins.
Keywords: Heart; Myocardial infarction; Galectin 3; Apoptosis.
© Copyright by the Author(s). Published by Cell Physiol Biochem Press.
Conflict of interest statement
The authors declare to have no competing interests.
Similar articles
-
Galectin-3 Mitigates Cardiomyocytes Injury through Modulation of Left Ventricular Cathepsins B, D, L and S at 24-Hour Post Myocardial Infarction.Cell Physiol Biochem. 2022 Apr 13;56(2):150-165. doi: 10.33594/000000510. Cell Physiol Biochem. 2022. PMID: 35413750
-
Myocardial Ischemia Reperfusion Injury: Apoptotic, Inflammatory and Oxidative Stress Role of Galectin-3.Cell Physiol Biochem. 2018;50(3):1123-1139. doi: 10.1159/000494539. Epub 2018 Oct 24. Cell Physiol Biochem. 2018. PMID: 30355930
-
Galectin-3 is expressed in the myocardium very early post-myocardial infarction.Cardiovasc Pathol. 2015 Jul-Aug;24(4):213-23. doi: 10.1016/j.carpath.2014.12.001. Epub 2014 Dec 9. Cardiovasc Pathol. 2015. PMID: 25547609
-
Value of Galectin-3 in Acute Myocardial Infarction.Am J Cardiovasc Drugs. 2020 Aug;20(4):333-342. doi: 10.1007/s40256-019-00387-9. Am J Cardiovasc Drugs. 2020. PMID: 31784887 Review.
-
Why anti-Bcl-2 clinical trials fail: a solution.Cancer Metastasis Rev. 2014 Mar;33(1):285-94. doi: 10.1007/s10555-013-9450-8. Cancer Metastasis Rev. 2014. PMID: 24338002 Free PMC article. Review.
Cited by
-
The Role of Galectin-3 in Heart Failure-The Diagnostic, Prognostic and Therapeutic Potential-Where Do We Stand?Int J Mol Sci. 2023 Aug 23;24(17):13111. doi: 10.3390/ijms241713111. Int J Mol Sci. 2023. PMID: 37685918 Free PMC article. Review.
-
The interplay of galectins-1, -3, and -9 in the immune-inflammatory response underlying cardiovascular and metabolic disease.Cardiovasc Diabetol. 2022 Nov 19;21(1):253. doi: 10.1186/s12933-022-01690-7. Cardiovasc Diabetol. 2022. PMID: 36403025 Free PMC article. Review.
-
Early Doxorubicin Myocardial Injury: Inflammatory, Oxidative Stress, and Apoptotic Role of Galectin-3.Int J Mol Sci. 2022 Oct 18;23(20):12479. doi: 10.3390/ijms232012479. Int J Mol Sci. 2022. PMID: 36293342 Free PMC article.
-
Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.Mol Med Rep. 2021 Oct;24(4):685. doi: 10.3892/mmr.2021.12325. Epub 2021 Jul 30. Mol Med Rep. 2021. Retraction in: Mol Med Rep. 2024 Sep;30(3):152. doi: 10.3892/mmr.2024.13275. PMID: 34328195 Free PMC article. Retracted.
-
Galectin-3 critically mediates the hepatoprotection conferred by M2-like macrophages in ACLF by inhibiting pyroptosis but not necroptosis signalling.Cell Death Dis. 2022 Sep 8;13(9):775. doi: 10.1038/s41419-022-05181-1. Cell Death Dis. 2022. PMID: 36075893 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous